Article

Adjustability a plus for microkeratomes

Author(s):

Lynda Charters

Tampere, Finland-Both the M2 Single Use microkeratome and the M2 microkeratome with the new 90-?m head (Moria, Antony, France) have been performing well in clinical trials.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) Introducing iOpeners: Unpacking high-yield ophthalmology tips and clinical pearls, with Nicole Bajic, MD
Related Content
First patient dosed in Qlaris Bio's phase 2 Nightingale clinical trial for QLS-111
August 26th 2025

First patient dosed in Qlaris Bio's phase 2 Nightingale clinical trial for QLS-111

3 Things You Should Know About the GA Pipeline
August 26th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Post-LASIK presbyopia: Meeting expectations with evolving technology
August 26th 2025

Post-LASIK presbyopia: Meeting expectations with evolving technology

Patient-Centered Treatment Strategies in the Management of nAMD and DME
August 26th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Possible protective role of cannabis in preventing postoperative proliferative vitreoretinopathy after retinal detachment repair
August 26th 2025

Possible protective role of cannabis in preventing postoperative proliferative vitreoretinopathy after retinal detachment repair

Kriya Therapeutics raises $313.3 funding
August 26th 2025

Kriya Therapeutics raises $313.3 funding

© 2025 MJH Life Sciences

All rights reserved.